Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IL-15–expressing CAR-T cell therapy
- Development stage
- Unknown
- Lead developer
- Tianjin Cancer Hospital Airport Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
IL-15–expressing CAR-T cell therapy is an adoptive cell therapy platform where T cells are genetically engineered to express both a chimeric antigen receptor (CAR) and the cytokine interleukin-15 (IL-15). IL-15 is a critical factor for the survival, proliferation, and metabolic fitness of T cells and natural killer (NK) cells. By co-expressing IL-15, these CAR-T cells aim to overcome the limitations of poor persistence and exhaustion often observed in conventional CAR-T therapies, particularly within the immunosuppressive tumor microenvironment. The specific program developed by Tianjin Cancer Hospital Airport Hospital (as seen in trial ChiCTR2500107167) utilizes this platform to target various hematologic antigens, including CD19, CD20, CD22, BCMA, CD7, and GPRC5D, for the treatment of a wide range of relapsed or refractory B-cell and T-cell malignancies, multiple myeloma, and plasma cell leukemia.
- Other names
- IL-15–expressing CAR-T cell therapyNovel IL-15–expressing CAR-T
02
Targets
BCMA (B-cell maturation antigen)CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)GPRC5DIL15 (Interleukin 15)CD22 (Cluster of Differentiation 22)CD7 (CD7 antigen)
Beyond the preview
Go deeper on IL-15–expressing CAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IL-15–expressing CAR-T cell therapy.